Malignant Brain Tumors In Children Will Soon Be Able To Be Curable – Part 2 of 3
The slip has already been shown to have some effectiveness in adults with medulloblastoma that has recurred, as well as with basal cell carcinoma, a type of skin cancer. Thirteen children with recurrent or drug-resistant brain tumors took GDC-0449 once a heyday for 28 days at one of two doses. The median age of the participants was about 12.
Twelve of the participants stayed the course without major side effects. One child was able to go on taking the drug for a full year without the cancer progressing. “This demonstrates that we have taken a tumor, found a molecular subtype, found a drug which works, showed that it’s safe in children and that we can have them benefit by treating these tumors using this molecular targeted therapy,” said Gajjar, who is kingpin of neuro-oncology in the department of oncology at St Jude Children’s Research Hospital in Memphis. The research group will be moving on to a phase 2 trial.